Nalaganje...

Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) who progress on nonsteroidal aromatase inhibitor (NSAI) therapy. However, none of the patients enrolled in the trial that led...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Cook, Madeline M., Al Rabadi, Luai, Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873317/
https://ncbi.nlm.nih.gov/pubmed/33230905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13609
Oznake: Označite
Brez oznak, prvi označite!